Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 33.35 INR
Change Today -0.25 / -0.74%
Volume 323.7K
ISL On Other Exchanges
Symbol
Exchange
Natl India
As of 7:06 AM 06/3/15 All times are local (Market data is delayed by at least 15 minutes).

ind-swift laboratories ltd (ISL) Snapshot

Open
34.50
Previous Close
33.60
Day High
35.00
Day Low
32.60
52 Week High
07/3/14 - 57.60
52 Week Low
12/17/14 - 22.05
Market Cap
1.4B
Average Volume 10 Days
348.8K
EPS TTM
-29.14
Shares Outstanding
41.0M
EX-Date
09/20/11
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IND-SWIFT LABORATORIES LTD (ISL)

Related News

No related news articles were found.

ind-swift laboratories ltd (ISL) Related Businessweek News

No Related Businessweek News Found

ind-swift laboratories ltd (ISL) Details

Ind-Swift Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India and internationally. The company operates through Bulk Drugs & Pharmaceuticals segment. It primarily offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, antimigraine, Parkinson disease, hyperparathyroidism, analgesic, aromatase inhibitor, nootropic, antihypertensive, antibacterial Quinolone, antidiarrhoeal, alcohol abstinence, antineoplastic, prostatic hyperplasia, and treatment of premature ejaculation; and others in glucocorticoids therapeutic area. The company also provides various products that are under development stage in prostatic hypertrophy, overactive bladder syndrome, and osteoporosis therapeutic areas. In addition, it offers menthol and mint derivatives under the Ind COOL brand. Further, the company provides contract research and manufacturing services, including early phase drug development, process research and development, custom chemical synthesis, contract and API manufacturing, and FTE, as well as analytical and regulatory submission support services. Ind-Swift Laboratories Limited was founded in 1995 and is based in Manimajra, India.

Founded in 1995

ind-swift laboratories ltd (ISL) Top Compensated Officers

Vice Chairman, Managing Director, Chairman of...
Total Annual Compensation: 18.0M
Joint Managing Director, Whole Time Director ...
Total Annual Compensation: 18.0M
Executive Director
Total Annual Compensation: 4.8M
Compensation as of Fiscal Year 2014.

ind-swift laboratories ltd (ISL) Key Developments

Ind-Swift Laboratories Ltd. Reports Audited Standalone Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015 and Audited Consolidated Earnings Results for the Full Year Ended March 31, 2015

Ind-Swift Laboratories Ltd. reported audited standalone earnings results for the fourth quarter and full year ended March 31, 2015 and audited consolidated earnings results for the full year ended March 31, 2015. For the quarter, on standalone basis, the company reported net sales or income from operations of INR 1,467.263 million compared to INR 2,098.987 million for the same period a year ago. Loss from operations before other income, interest and exceptional item was INR 121.700 million compared to loss from operations before other income, interest and exceptional item of INR 529.130 million for the same period a year ago. Net loss from ordinary activities after tax was INR 709.059 million compared to INR 927.205 million for the same period a year ago. Basic and diluted loss per share was INR 17.31 compared to INR 22.12 for the same period a year ago. For the year, on standalone basis, the company reported net sales or income from operations of INR 6,457.367 million compared to INR 9,406.615 million for the same period a year ago. Profit from operations before other income, interest and exceptional item was INR 270.920 million compared to profit from operations before other income, interest and exceptional item of INR 48.140 million for the same period a year ago. Loss from ordinary activities before tax was INR 1,432.854 million compared to INR 1,432.062 million for the same period a year ago. Net loss from ordinary activities after tax was INR 1,191.634 million compared to INR 1,227.436 million for the same period a year ago. Basic and diluted loss per share was INR 29.09 compared to INR 29.28 for the same period a year ago. For the year, on consolidated basis, the company reported net sales or income from operations of INR 6,604.523 million compared to INR 9,650.825 million for the same period a year ago. Profit from operations before other income, interest and exceptional item was INR 270.268 million compared to profit from operations before other income, interest and exceptional item of INR 59.790 million for the same period a year ago. Loss from ordinary activities before tax was INR 1,433.505 million compared to INR 1,420.630 million for the same period a year ago. Net loss from ordinary activities after tax was INR 1,193.496 million compared to INR 1,220.121 million for the same period a year ago. Basic and diluted loss per share was INR 29.14 compared to INR 29.11 for the same period a year ago.

Ind-Swift Laboratories Ltd. to Report Q4, 2015 Results on May 16, 2015

Ind-Swift Laboratories Ltd. announced that they will report Q4, 2015 results on May 16, 2015

Ind-Swift Laboratories Ltd., Board Meeting, May 16, 2015

Ind-Swift Laboratories Ltd., Board Meeting, May 16, 2015. Agenda: To consider the audited financial results for the fourth quarter and financial year ended March 31, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ISL:IN 33.35 INR -0.25

ISL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $48.86 USD -0.08
View Industry Companies
 

Industry Analysis

ISL

Industry Average

Valuation ISL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IND-SWIFT LABORATORIES LTD, please visit www.indswiftlabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.